---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352193"
form_type: "8-K/A"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2026-08-14T20:05:17+00:00"
generated_at: "2026-08-14T20:10:24.618555+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio Q2 net loss narrows to $3.9M; cash $320.4M, pipeline advances

## Summary
- Q2 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) year ago; Gilead revenue $13.4M vs $9.6M.
- Cash, equivalents, marketable securities $320.4M at June 30, 2026; $115M gross financing completed; runway into 2029.
- ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 expected Q1 2027.
- GS-1179 selected for Phase 2 in recurrent genital herpes by year-end 2026; opt-in decision on 40% U.S. cost-profit share pending Gilead cost estimates.
- $75M Gilead extension payment due Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-352193
- form_type: 8-K/A
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2026-08-14T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312526352193/0001193125-26-352193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312526352193/asmb-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352193
- JSON: https://secwatch.observer/filing/0001193125-26-352193.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.